Imexon
| Title | Journal |
|---|---|
| Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423. | Cancer chemotherapy and pharmacology 20120401 |
| Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells. | Molecular cancer research : MCR 20120301 |
| Chemistry and pharmacology of imexon and related cyanoaziridines. | Current medicinal chemistry 20120101 |
| Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells. | Anticancer research 20110901 |
| Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase. | Cancer chemotherapy and pharmacology 20110101 |
| A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. | Investigational new drugs 20101001 |
| A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. | Cancer 20100801 |
| Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma. | Anti-cancer drugs 20100801 |
| A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer. | Cancer chemotherapy and pharmacology 20100701 |
| Redox-directed cancer therapeutics: molecular mechanisms and opportunities. | Antioxidants & redox signaling 20091201 |
| Imexon augments sensitivity of human lymphoma cells to ionizing radiation: in vitro experimental study. | Anticancer research 20091101 |
| Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells. | Investigational new drugs 20090201 |
| New analytical techniques to facilitate preformulation screening in propellant systems. | International journal of pharmaceutics 20070801 |
| The antitumor agent imexon activates antioxidant gene expression: evidence for an oxidative stress response. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070601 |
| Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines. | Cancer chemotherapy and pharmacology 20070501 |
| Phase I trial of imexon in patients with advanced malignancy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070501 |
| Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice. | Anti-cancer drugs 20061101 |
| Preformulation studies on imexon. | Drug development and industrial pharmacy 20060701 |
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| Oxidative stress and apoptosis: a new treatment paradigm in cancer. | Frontiers in bioscience : a journal and virtual library 20060101 |
| Correlates of imexon sensitivity in human multiple myeloma cell lines. | Leukemia & lymphoma 20060101 |
| Targeting mitochondria emerges as therapeutic strategy. | Journal of the National Cancer Institute 20051221 |
| Rob Ashley of AmpliMed discusses the discovery and development of Imexon. Interview by Steve Carney. | Drug discovery today 20051015 |
| Compatibility and stability of Imexon in infusion devices and its in vitro biocompatibility. | Anti-cancer drugs 20050801 |
| LC-UV method development and validation for the investigational anticancer agent imexon and identification of its degradation products. | Journal of pharmaceutical and biomedical analysis 20050715 |
| Pharmaceutical development of a lyophilised dosage form for the investigational anticancer agent Imexon using dimethyl sulfoxide as solubilising and stabilising agent. | Journal of pharmaceutical sciences 20050501 |
| Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines. | International journal of gastrointestinal cancer 20050101 |
| Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040215 |
| Chemical basis for the biological activity of imexon and related cyanoaziridines. | Journal of medicinal chemistry 20040101 |
| Cytotoxic effects of B lymphocytes mediated by reactive oxygen species. | Current pharmaceutical design 20040101 |
| Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells. | Anti-cancer drugs 20021101 |
| Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells. | Molecular cancer therapeutics 20020101 |
| Induction of mitochondrial changes in myeloma cells by imexon. | Blood 20010601 |
| Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon. | Biochemical pharmacology 20000915 |
| Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro. | Journal of the National Cancer Institute 19920819 |
| Antiviral efficacy of Imexon in the Rauscher murine retrovirus AIDS model. | Immunopharmacology and immunotoxicology 19900101 |